Alpha memo: urolithin mitochondrial aging signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Either (a) reframe the memo around an actual directional tension supported by the receipts (e.g., tissue-specific mitochondrial mechanisms of UroA across cardiac vs neural tissue), or (b) replace one receipt with a null/contradictory finding so the non-transfer claim becomes falsifiable rather than trivial.
2. Explicitly address the UroA vs mUroA compound distinction and justify treating them as the same anchor, or narrow the title/anchor to one compound.
3. Upgrade Receipt 1 to a peer-reviewed source if available, or flag the preprint status prominently.
4. Tighten the alpha to a single, bounded, receipt-grounded claim — not a methodological caveat about cross-study non-comparability.

Major issues

• The memo's central 'alpha' — that urolithin/mitochondrial does not carry one stable direction across the two receipts — is not actually supported by the cited evidence. Both receipts report positive findings (UroA cardioprotection; mUroA cognitive benefit). Neither receipt contradicts the other; they simply study different endpoints (cardiac vs cognitive), different compounds (UroA vs methylated UroA), and different models (natural aging/HF vs D-gal-induced aging). A non-transfer finding requires at least one negative or null receipt, which is absent.
• The memo treats endpoint/setting heterogeneity as if it were a directional contradiction. A bounded contrast across endpoints is not a falsifiable alpha signal — it is a scoping observation. The title promises a 'mitochondrial aging signal' but the body delivers only a methodological caveat about non-comparability.
• Title/source alignment is borderline: the memo anchors on 'urolithin' broadly, but Receipt 2 uses methylated urolithin A (mUroA), a structurally distinct compound. This is not flagged or reconciled; the memo treats them as the same anchor without justification.
• The bounded-contrast framing ('Receipt 1 signal does not automatically transfer to Receipt 2') is trivially true for any two non-identical studies and provides no actionable research signal.

Minor issues

• Receipt 1 is a bioRxiv preprint, not a peer-reviewed publication; this should be disclosed.
• The 'Why this is surprising' section claims novelty via a truism (same anchor ≠ same result) without grounding it in a specific literature tension.
• Falsifier is stated in general terms ('matched human or field study') without specifying which endpoint or compound.

Reviewer note

The memo attempts a bounded contrast between two urolithin/mitochondrial/aging receipts but fails at the foundational level: both receipts report positive effects on different endpoints in different models. There is no directional contradiction to map, so the 'non-transfer' alpha is not a research signal — it is a scoping truism. The structural conflation of UroA with methylated UroA compounds the problem. The title promises a 'mitochondrial aging signal' but the body delivers only a methodological caveat. This needs a scope reset: either find a receipt that genuinely contests the other, or reframe around a tissue-specific mechanism comparison that the evidence actually supports.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis